Globeimmune, Inc.

Louisville, CO 80027

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $1.1MM
First Award Date 09/30/96
Most Recent Award Date 08/01/01

Key Personnel

Last Name Name Awards Contact
Duke Richard C Duke 5
Bellgrau Donald Bellgrau 1

6 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/01 - 07/31/02

DESCRIPTION: (Adapted from the applicant's abstract) Preliminary studies by several groups, including those funded in part by the phase I SBIR award R43-AI40394 to CERES Pharmaceuticals, have demonstrated the potential for FasL-based therapy to prevent transplantation rejection, to treat autoimmune diseas...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/01 - 12/31/01

DESCRIPTION: Preliminary reports by several groups have demonstrated the potential for Fas ligand-based therapy to prevent transplant rejection, to treat autoimmune disease, to induce immunological tolerance and to treat cancer. The "Use of Fas Ligand to Suppress T-lymphocyte mediated Immune Respons...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/00 - 07/31/01

DESCRIPTION: (Adapted from the applicant's abstract) Preliminary studies by several groups, including those funded in part by the phase I SBIR award R43-AI40394 to CERES Pharmaceuticals, have demonstrated the potential for FasL-based therapy to prevent transplantation rejection, to treat autoimmune diseas...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/99 - 07/31/00

DESCRIPTION: (Adapted from the applicant's abstract) Preliminary studies by several groups, including those funded in part by the phase I SBIR award R43-AI40394 to CERES Pharmaceuticals, have demonstrated the potential for FasL-based therapy to prevent transplantation rejection, to treat autoimmune diseas...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/98 - 03/31/00

DESCRIPTION: (From the applicant's abstract) Cytotoxic T cell (CTL) immunity is considered to play a major role in reducing viral load early in HIV infection, and in slowing the rate of progression to AIDS. However, most of the current HIV vaccines in advanced human clinical trials, those consistin...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/96 - 03/31/97